Stifel Cuts Boston Scientific (BSX) Price Target to $55

By TradeTexts Research Desk Oct 26, 2026, 2:15 PM EDT

Key Points

Stifel reduced its price target for Boston Scientific from $60 to $55 but kept a Buy rating on the stock.
Stifel's $55 price target implies 21.43% upside from Boston Scientific Corporation's ($BSX) current $45.30 share price.
The stock recently traded around $45.30, which is about equal to its closing price of $45.38 on the same day.
Boston Scientific has a market cap of approximately $66.2 billion and is part of the medical devices industry.

Get Boston Scientific text alerts

We text you when insiders, Congress, analysts or big funds move on $BSX.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Boston Scientific Corporation alert may contain errors. Disclosures

On October 26, 2026, Stifel lowered its price target for Boston Scientific Corporation (BSX) to $55 from $60 while maintaining a Buy rating. This adjustment reflects Stifel's ongoing analysis of the company's market position and potential.

Stifel's new price target indicates a cautious outlook, given that the stock was recently trading around $45.30, which is about equal to its closing price of $45.38 on the same day. The stock is currently below its 50-day moving average by about 0.5% and is significantly lower than its 200-day moving average by about 21.7%. Additionally, it is down approximately 57.1% from its 52-week high of $105.65.

BSX Boston Scientific Corporation

$45.69 -51.76% year to date

Daily close · Oct 23, 2026

Analyst rating track record

Stifel vs. the S&P 500

YTD return -7.82% hypothetical

All-time return -7.82% S&P 500 +1.18%

vs. S&P 500 -9% behind the index

Hypothetical returns from Stifel's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Boston Scientific

Primecap Management Company holds about 50.5 million shares of Boston Scientific, having increased its stake by nearly 17.99 million shares. Shaw D.E. & Co., Inc. owns approximately 25.5 million shares, with a slight increase of about 1.15 million shares. Massachusetts Financial Services Co. also raised its position, now holding around 24.9 million shares after adding about 13.86 million shares.

Boston Scientific Corporation Stock Down 1.6%

Boston Scientific's stock trades significantly below its 52-week high and is currently around $45.30. This price is about 17.6% below the average analyst target of $57.82, indicating that analysts see potential for growth despite recent price adjustments.

12-month forecast

$BSX price target

Boston Scientific Corporation daily closes and this analyst's $55 target. Not advice.

Recent Earnings

Boston Scientific reported trailing twelve-month revenue of approximately $20.99 billion and an EPS of $2.47. The company has shown a revenue growth of 7.5% year-over-year, and its next earnings report is scheduled for October 28, 2026.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

F 28/100

Reported Apr 22, 2026

Forward outlook
12 target cuts vs 1 raises.
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
Pre-earnings setup
Bar was high, analysts already very bullish.
Analyst signal
1 target raise, 12 target cuts.
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.

Earnings Call Summary

Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.

Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.

Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.

Insider Buying and Selling at Boston Scientific Corporation

Several insiders have made purchases in recent months. CEO Michael F. Mahoney bought 186,240 shares at an average price of $48.33 on August 3, 2026. Director David C. Habiger purchased 1,182 shares on August 4, 2026, followed by another buy of 2,100 shares at $47.59 on August 5, 2026. Director Susan E. Morano also acquired 2,040 shares at $49.22 on August 25, 2026.

Analysts Set New Price Targets

On October 26, 2026, Stifel maintained its Buy rating on Boston Scientific while lowering its price target to $55 from $60. This adjustment comes as part of a broader trend, as other analysts like Wells Fargo and Citigroup have also recently adjusted their targets to $48.

About Boston Scientific

Boston Scientific Corporation develops and markets medical devices used in various interventional medical specialties worldwide. The company operates in two main segments: MedSurg and Cardiovascular. Given the ongoing changes in its price targets, the company's performance is closely watched by investors and analysts alike.

Bottom Line

Looking ahead, investors should watch for Boston Scientific's upcoming earnings report on October 28, 2026, for further insights into its financial health. The recent target changes from analysts like Stifel highlight the mixed sentiment around the stock's future performance.